PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTrientine
Syprine, Cuprior(trientine)
Cufence, Cuprior, Syprine, Trientine (trientine) is a small molecule pharmaceutical. Trientine was first approved as Syprine on 1985-11-08. It is used to treat hepatolenticular degeneration and nervous system heavy metal poisoning in the USA. It has been approved in Europe to treat hepatolenticular degeneration.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Cuvrior, Syprine, Trientine (discontinued: Clovique, Trientine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trientine hydrochloride
Tradename
Company
Number
Date
Products
SYPRINEBausch Health CompaniesN-019194 RX1985-11-08
1 products, RLD, RS
Trientine tetrahydrochloride
Tradename
Company
Number
Date
Products
CUVRIOROrphalanN-215760 RX2022-04-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cuvriorNew Drug Application2025-03-04
syprineNew Drug Application2020-09-01
trientine hydrochlorideANDA2025-02-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatolenticular degenerationOrphanet_905D006527E83.01
nervous system heavy metal poisoningEFO_1001815D020260—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AX: Various alimentary tract and metabolism products
— A16AX12: Trientine
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatolenticular degenerationD006527Orphanet_905E83.01————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTrientine
INNtrientine
Description
2,2,2-tetramine is a polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens. It has a role as a copper chelator. It is a tetramine and a polyazaalkane.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NCCNCCNCCN
Identifiers
PDB—
CAS-ID112-24-3
RxCUI—
ChEMBL IDCHEMBL609
ChEBI ID39501
PubChem CID5565
DrugBankDB06824
UNII IDSJ76Y07H5F (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Clovique – Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,384 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
325 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use